Related Experiment Video
Updated: May 6, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced
1College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Abstract:
MicroRNAs (miRNAs) have a role in the cellular defense mechanism. Nuclear factor erythroid-2-related factor 2 (Nrf2) increases antioxidant enzyme capacity. However, miRNA transcriptionally controlled by Nrf2 had been uncharacterized. Here we report that miR-125b is transactivated by Nrf2 and inhibits aryl hydrocarbon receptor (AhR) repressor (AhRR). Bioinformatic approaches enabled us to extract six candidate miRNAs. Of them, only miR-125b was increased in the kidney of mice treated with oltipraz. Nrf2 overexpression enhanced primary, precursor and mature miR-125b levels. Functional assays revealed MIR125B1 is a bona fide target gene of Nrf2. Oltipraz treatment protected the kidney from cisplatin toxicity with increase of miR-125b. Consistently, Nrf2 knockout abrogated an adaptive increase of miR-125b elicited by cisplatin, augmenting kidney injury. An integrative network of miRNA and messenger RNA changes enabled us to predict miR-125b as an inhibitor of AhRR for the control of AhR activity and cell survival. In our molecular study, miR-125b inhibited AhRR and thereby activated AhR, leading to the induction of mdm2. Consistently, p53 activation by cisplatin was diminished by either miR-125b or oltipraz treatment. The results of experiments using miR-125b mimic or small interfering RNA of AhRR verified the role of miR-125b in AhRR regulation for kidney protection. In conclusion, miR-125b is transcriptionally activated by Nrf2 and serves as an inhibitor of AhRR, which contributes to protecting kidney from acute injury.
Insights
Nuclear factor erythroid-2-related factor 2 (Nrf2) activates miR-125b, which protects the kidney from injury by inhibiting the aryl hydrocarbon receptor repressor (AhRR). This pathway enhances cellular defense mechanisms against toxins.
Area of Science:
- Molecular Biology
- Cellular Biology
- Toxicology
Background:
- MicroRNAs (miRNAs) are key regulators of cellular defense mechanisms.
- Nuclear factor erythroid-2-related factor 2 (Nrf2) enhances antioxidant capacity but its control over miRNAs is uncharacterized.
- Understanding Nrf2-regulated miRNAs is crucial for cellular protection strategies.
Purpose of the Study:
- To identify and characterize miRNAs transcriptionally regulated by Nrf2.
- To investigate the role of a novel Nrf2-regulated miRNA in kidney protection.
- To elucidate the molecular mechanism of miR-125b in regulating aryl hydrocarbon receptor (AhR) activity and cellular survival.
Main Methods:
- Bioinformatic analysis to identify candidate miRNAs.
- In vivo studies using mice treated with oltipraz and cisplatin.
- Nrf2 overexpression and knockout models.
- Functional assays including miR-125b mimic and small interfering RNA (siRNA) for AhRR.
- Analysis of gene and protein expression levels (e.g., AhRR, mdm2, p53).
Main Results:
- miR-125b was identified as a direct Nrf2 target gene, upregulated by oltipraz and cisplatin.
- Nrf2 overexpression increased miR-125b levels; Nrf2 knockout exacerbated cisplatin-induced kidney injury.
- miR-125b was found to inhibit AhRR, leading to AhR activation and mdm2 induction.
- miR-125b and oltipraz treatment diminished p53 activation by cisplatin, protecting the kidney.
- Experiments confirmed miR-125b's role in AhRR regulation and kidney protection.
Conclusions:
- miR-125b is transcriptionally activated by Nrf2.
- miR-125b acts as a crucial inhibitor of AhRR, modulating AhR activity.
- This Nrf2-miR-125b-AhRR axis plays a significant role in protecting the kidney from acute injury.
Related Concept Videos
Master Transcription Regulators
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Co-activators and Co-repressors

